FATE THERAPEUTICS INC Net Cash Provided by (Used in) Operating Activities, Continuing Operations
FATE THERAPEUTICS INC (FATE) reported Net Cash Provided by (Used in) Operating Activities, Continuing Operations of -$30.80 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations · last filed 2026-05-13
- FATE THERAPEUTICS INC net cash provided by (used in) operating activities, continuing operations for the quarter ending 2026-03-31 was -$30.80M.
- FATE THERAPEUTICS INC net cash provided by (used in) operating activities, continuing operations for the quarter ending 2018-03-31 was -$12.55M.
- FATE THERAPEUTICS INC net cash provided by (used in) operating activities, continuing operations for the quarter ending 2017-12-31 was -$10.72M.
- FATE THERAPEUTICS INC net cash provided by (used in) operating activities, continuing operations for the quarter ending 2017-09-30 was -$9.86M.
- FATE THERAPEUTICS INC net cash provided by (used in) operating activities, continuing operations for fiscal 2017 was -$36.91M.
- FATE THERAPEUTICS INC net cash provided by (used in) operating activities, continuing operations for fiscal 2016 was -$29.82M.
- FATE THERAPEUTICS INC net cash provided by (used in) operating activities, continuing operations for fiscal 2015 was -$18.40M.
- FATE THERAPEUTICS INC net cash provided by (used in) operating activities, continuing operations for fiscal 2014 was -$22.42M.
| Period end | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 12 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 77 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 80 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 83 month |
|---|---|---|---|---|---|---|---|
| 2026-03-31 | -$30.80M 10-Q · filed 2026-05-13 | ||||||
| 2018-03-31 | -$12.55M 10-Q · filed 2018-05-10 | -$23.27M derived: sum of 2 quarters · filed 2018-05-10 | -$33.13M derived: sum of 3 quarters · filed 2018-05-10 | -$42.00M derived: sum of 4 quarters · filed 2018-05-10 | |||
| 2017-12-31 | -$10.72M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-05 | -$20.58M derived: sum of 2 quarters · filed 2018-03-05 | -$29.45M derived: sum of 3 quarters · filed 2018-03-05 | -$36.91M 10-K · filed 2018-03-05 | |||
| 2017-09-30 | -$9.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | -$18.73M derived: sum of 2 quarters · filed 2017-11-01 | -$26.18M 10-Q · filed 2017-11-01 | -$33.73M derived: sum of 4 quarters · filed 2018-05-10 | |||
| 2017-06-30 | -$8.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | -$16.33M 10-Q · filed 2017-08-14 | -$23.88M derived: sum of 3 quarters · filed 2018-05-10 | -$31.39M derived: sum of 4 quarters · filed 2018-05-10 | |||
| 2017-03-31 | -$7.46M 10-Q · filed 2018-05-10 | -$15.01M derived: sum of 2 quarters · filed 2018-05-10 | -$22.52M derived: sum of 3 quarters · filed 2018-05-10 | -$30.03M derived: sum of 4 quarters · filed 2018-05-10 | |||
| 2016-12-31 | -$7.55M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-05 | -$15.07M derived: sum of 2 quarters · filed 2018-03-05 | -$22.57M derived: sum of 3 quarters · filed 2018-03-05 | -$29.82M 10-K · filed 2018-03-05 | |||
| 2016-09-30 | -$7.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | -$15.02M derived: sum of 2 quarters · filed 2017-11-01 | -$22.27M 10-Q · filed 2017-11-01 | -$29.24M derived: sum of 4 quarters · filed 2018-03-05 | |||
| 2016-06-30 | -$7.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | -$14.76M 10-Q · filed 2017-08-14 | -$21.73M derived: sum of 3 quarters · filed 2018-03-05 | -$28.86M derived: sum of 4 quarters · filed 2018-03-05 | |||
| 2016-03-31 | -$7.25M 10-Q · filed 2017-05-15 | -$14.22M derived: sum of 2 quarters · filed 2018-03-05 | -$21.35M derived: sum of 3 quarters · filed 2018-03-05 | -$19.27M derived: sum of 4 quarters · filed 2018-03-05 | |||
| 2015-12-31 | -$6.97M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-05 | -$14.10M derived: sum of 2 quarters · filed 2018-03-05 | -$12.02M derived: sum of 3 quarters · filed 2018-03-05 | -$18.40M 10-K · filed 2018-03-05 | |||
| 2015-09-30 | -$7.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | -$5.05M derived: sum of 2 quarters · filed 2016-11-07 | -$11.43M 10-Q · filed 2016-11-07 | -$17.58M derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2015-06-30 | $2.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | -$4.30M 10-Q · filed 2016-08-08 | -$10.45M derived: sum of 3 quarters · filed 2017-03-16 | -$15.97M derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2015-03-31 | -$6.38M 10-Q · filed 2016-05-09 | -$12.53M derived: sum of 2 quarters · filed 2017-03-16 | -$18.05M derived: sum of 3 quarters · filed 2017-03-16 | -$23.54M derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2014-12-31 | -$6.15M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | -$11.68M derived: sum of 2 quarters · filed 2017-03-16 | -$17.16M derived: sum of 3 quarters · filed 2017-03-16 | -$22.42M 10-K · filed 2017-03-16 | |||
| 2014-09-30 | -$5.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-03 | -$11.01M derived: sum of 2 quarters · filed 2015-11-03 | -$16.27M 10-Q · filed 2015-11-03 | -$20.84M derived: sum of 4 quarters · filed 2016-03-03 | |||
| 2014-06-30 | -$5.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | -$10.74M 10-Q · filed 2015-08-05 | -$15.32M derived: sum of 3 quarters · filed 2016-03-03 | -$18.79M derived: sum of 4 quarters · filed 2016-03-03 | |||
| 2014-03-31 | -$5.25M 10-Q · filed 2015-05-07 | -$9.83M derived: sum of 2 quarters · filed 2016-03-03 | -$13.30M derived: sum of 3 quarters · filed 2016-03-03 | -$16.70M derived: sum of 4 quarters · filed 2016-03-03 | -$79.36M 10-Q · filed 2014-05-13 | ||
| 2013-12-31 | -$4.58M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-03 | -$8.05M derived: sum of 2 quarters · filed 2016-03-03 | -$11.44M derived: sum of 3 quarters · filed 2016-03-03 | -$15.37M 10-K · filed 2016-03-03 | -$74.11M 10-K · filed 2014-03-17 | ||
| 2013-09-30 | -$3.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | -$6.86M derived: sum of 2 quarters · filed 2014-11-12 | -$10.79M 10-Q · filed 2014-11-12 | -$14.19M derived: sum of 4 quarters · filed 2015-03-12 | -$69.53M 10-Q · filed 2013-11-13 | ||
| 2013-06-30 | -$3.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-12 | -$7.32M 10-Q · filed 2014-08-12 | -$10.72M derived: sum of 3 quarters · filed 2015-03-12 | ||||
| 2013-03-31 | -$3.93M 10-Q · filed 2014-05-13 | -$7.33M derived: sum of 2 quarters · filed 2015-03-12 | |||||
| 2012-12-31 | -$3.39M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | -$13.27M 10-K · filed 2015-03-12 | |||||
| 2012-09-30 | -$9.88M 10-Q · filed 2013-11-13 | ||||||
| 2011-12-31 | -$12.14M 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |